News
FATE
1.255
-2.71%
-0.035
Weekly Report: what happened at FATE last week (0106-0110)?
Weekly Report · 1d ago
Fate Therapeutics Announces Executive Leadership Transition
TipRanks · 01/06 21:32
Weekly Report: what happened at FATE last week (1230-0103)?
Weekly Report · 01/06 11:28
FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 01/03 21:01
Biotech Alert: Searches spiking for these stocks today
TipRanks · 12/30/2024 16:00
Weekly Report: what happened at FATE last week (1223-1227)?
Weekly Report · 12/30/2024 11:22
Insider Sale: Director at $FATE (FATE) Sells 341,633 Shares
NASDAQ · 12/27/2024 02:15
Weekly Report: what happened at FATE last week (1216-1220)?
Weekly Report · 12/23/2024 11:29
Weekly Report: what happened at FATE last week (1209-1213)?
Weekly Report · 12/16/2024 11:29
Barclays Gives a Buy Rating to Fate Therapeutics (FATE)
TipRanks · 12/11/2024 09:25
Hold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy Development
TipRanks · 12/10/2024 09:45
Fate Therapeutics Reports Positive Phase 1 Results for FT819 in Lupus Treatment with Favorable Safety Profile and Initiates Dose Expansion
Barchart · 12/10/2024 01:22
Fate Therapeutics presents new data from FT819 study
TipRanks · 12/09/2024 21:16
FATE THERAPEUTICS PRESENTS NEW PHASE 1 CLINICAL DATA OF FT819 OFF-THE-SHELF, CAR T-CELL PRODUCT CANDIDATE FOR SYSTEMIC LUPUS ERYTHEMATOSUS
Reuters · 12/09/2024 21:01
Weekly Report: what happened at FATE last week (1202-1206)?
Weekly Report · 12/09/2024 11:28
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Veeva Systems (VEEV) and Alcon (ALC)
TipRanks · 12/06/2024 12:31
Piper Sandler Remains a Buy on Fate Therapeutics (FATE)
TipRanks · 12/05/2024 18:21
FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARD UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/03/2024 21:01
Weekly Report: what happened at FATE last week (1125-1129)?
Weekly Report · 12/02/2024 11:29
Fate Therapeutics appoints new CEO as Scott Wolchko retires
Seeking Alpha · 12/02/2024 09:50
More
Webull provides a variety of real-time FATE stock news. You can receive the latest news about Fate Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.